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Age-Adjusted Incidence Rates and Time Trends of Non-Hodgkin Lymphoma by Subtype, 2000-2015
DaiTrang Le
University of Nebraska Medical Center

Abstract
Background: Non-Hodgkin lymphomas (NHL) are a group of diverse and complex cancers of the
lymphocytes. More than 60 subtypes have been identified based on certain characteristics of the cancer
cell. The objectives of this study were to: 1) determine NHL age-adjusted incidence rates from 2000 to
2015 in the U.S. by age, sex, and race/ethnicity; 2) to examine age-adjusted subtype-specific NHL
incidence rates by age, sex, and race/ethnicity; 3) to determine if there was significant time trend in ageadjusted NHL incidence rate from 2000-2015 in the U.S by age, sex, and race/ethnicity.; 4) and to
examine time trend in age-adjusted subtype-specific NHL incidence rate from 2000-2015 in the U.S. by
age, sex, and race/ethnicity.
Methods: We used Surveillance Epidemiology and End Results (SEER) Program registries of 18
geographical locations 2000-2015. There were a total of 259,228 incident cases of NHL. Subtypes were
coded using the World Health Organization (WHO) 2008 classification scheme and International
Classification of Disease – Oncology, 3rd Edition (ICD-O-3) site codes. Subgroups analyzes were based on
sex, race (white, black, American Indian/Alaska Native, or Asian/Pacific Islander), ethnicity (nonSpanish/Hispanic/Latino or Spanish/Hispanic/Latino) and age group (20-29, 30-39, 40-49, 50-59, 60-69,
or 70+). Age-adjusted incidence rates and rate ratios were calculated using SEER*Stat software.
Statistical significance was determined by comparing 95% confidence intervals. Annual percentage
change (APC) was calculated using Joinpoint regression software.
Results: All subtypes had decreasing incidence except mantle-cell lymphoma, which had increasing
incidence (APC 0.77%, p<0.05) and cutaneous T-cell lymphomas, which had a stabilized incidence (p=0.9).
All subtypes had a higher male incidence rates except marginal-zone lymphoma, which had similar
incidence rates in males and females (p=0.36). Whites had highest incidence rates in all subtypes except
cutaneous T-cell lymphomas and peripheral T-cell lymphomas, in which blacks had the highest incidence
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rates and significantly higher incidence rates than whites (RR=1.54, p<0.05; RR=1.90, p<0.05). NonHispanics had higher incidence in all subtypes except Diffuse Large B-Cell Lymphoma and Burkitt
Lymphoma, in which non-Hispanics had higher incidence rates (RR=1.05, p<0.05; RR=1.17, p<0.05).
Finally, incidence increases as age increases for all subtypes, although the increase is smaller in Burkitt
lymphoma, which is more common in younger populations.
Conclusion: Analysis by subtype and subgroups revealed incidence rates and time trends that were not
obvious when analyzing data for all subtypes of subpopulations combined. Some subgroups were at
higher risk than others, but only for certain subtypes, meaning that etiology and risk may vary by
subtype. This was apparent in the higher risk for blacks compared to whites in T-cell lymphomas and
Hispanics compared to non-Hispanics in diffuse large B-cell lymphoma and Burkitt lymphoma.
Understanding these differences can help us identify population-specific prevention methods and
treatments for each subtype.
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Background
Non-Hodgkin lymphoma (NHL) is a lymphoid neoplasm that starts in white blood cells called
lymphocytes. It is the seventh most common cancer and the ninth leading cause of cancer death in the
U.S. (American Cancer Society (ACS), 2017). It accounts for about 4% of all cancers in the U.S. (ACS,
2018). The World Health Organization (WHO) has identified more than 60 subtypes of NHL based on
certain characteristics of the cancer cell (Leukemia and Lymphoma Society, 2015). Some characteristics
that determine WHO subtype include the type of lymphocyte affected (B-cell, T-cell, or NK cell), the rate
of cancer growth (indolent or aggressive), and the location of the cancer (e.g., spleen, lymph nodes,
bone marrow) (ACS, 2018). Some of the most common subtypes of non-Hodgkin lymphoma are Diffuse
Large B-Cell lymphoma (33% of cases), follicular lymphoma (20% of cases), mantle-cell lymphoma (5-7%
of cases), and small-cell lymphoma (5% of cases) (ACS, 2017).
Because of the abundance of subtypes of non-Hodgkin lymphoma and the complexity of the
disease, classification of NHL has evolved many times over the years. In the 1960s, the Rappaport
classification was used, which focused on the appearance of cancer cells. Small cells were “lymphocytic”
and large cells were “histiocytic” (Jaffe et al., 1992). The Rye classification, which focused on prognosis
(most favorable, favorable, guarded, least favorable), was also used (National Cancer Institute (NCI),
2018). The Kiel classification focused on the type of lymphocyte affected (B-cell or T-cell) and tumor
grade (high or low) (NCI, 2018). In 1982, the Working Formulation (WF) was developed and combined
many previous classification schemes and grouped according to prognosis and tumor grade (NCI, 2018).
In 1994, the International Lymphoma Study group published the Revised European-American Lymphoma
(REAL) system that was used as a basis for the WHO classification in 2001 (Campo et al., 2011). The
introduction of the WHO classification system in 2001 resolved many issues regarding lymphoma
classification and recognized more subtypes based on morphology, immunophenotype, genetic,
molecular, and clinical features (Campo et al., 2011). The system was revised in 2008 and its terminology
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has been incorporated into the International Classification of Diseases – Oncology, 3rd Edition (ICD-O-3)
codes used by the Surveillance, Epidemiology, and End Results (SEER) Program (NCI, n.d.).
Between 1970 and 1980, NHL age-adjusted incidence rate in the U.S. increased annually by 3-4%.
During the 1990s, this dropped to <1% increase per year (Howe et al., 2001). However, trends over time
may be misleading without subgroup analysis as observed with other types of cancer. For example,
overall breast cancer mortality rate has decreased from 2002 to 2011 (Average annual percentage
change (AAPC) -0.2%) (Kohler et al., 2015). Further analysis by race/ethnicity found that this decrease
trend was driven by the decrease in the mortality rate among Non-Hispanic Whites. Among African
American and Asian/Pacific Islander (API) women the mortality rate actually increased (AAPC 0.7%,
p<0.05; AAPC 0.8%, P>0.05) Kohler et al., 2015). Another example is colorectal cancer trends. While the
overall colorectal cancer incidence and mortality rates decreased from 2000 to 2013, the incidence rate
in younger individuals (<50 years old) increased substantially (5.9 to 7.2 per 100,000) and the mortality
rate remained the same (Siegel et al., 2017).
An examination of incidence and mortality rates by race/ethnicity and age group can provide
important clues to further understanding the etiology of the disease and potential differences in
response to treatment (Rudan et al., 2013; Koivunen et al., 2015). Furthermore, each subtype of NHL
may have different risk factors, some of which may be exacerbated in different demographic subgroups.
Therefore, understanding the heterogeneity of NHL can help us identify populations with higher risk and
burden of cancer. The objectives of this study were to: 1) determine NHL age-adjusted incidence rates
from 2000 to 2015 in the U.S. by age, sex, and race/ethnicity; 2) to examine age-adjusted subtypespecific NHL incidence rates by age, sex, and race/ethnicity; 3) to determine if there was significant time
trend in age-adjusted NHL incidence rate from 2000-2015 in the U.S by age, sex, and race/ethnicity.; 4)
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and to examine time trend in age-adjusted subtype-specific NHL incidence rate from 2000-2015 in the
U.S. by age, sex, and race/ethnicity.
Methods
Data were obtained from the SEER Program’s database, which contains data from 18
geographical registries (standard metropolitan statistical area of San Francisco (SF)/Oakland,
Connecticut, Metropolitan Detroit, Seattle/Puget Sound, Metropolitan Atlanta, San-Jose/Monterey
(SJM), Los Angeles (LA), Alaska Natives, Rural Georgia, Greater Georgia, California (excluding
SF/SJM/LA), Hawaii, Iowa, New Mexico, Utah, Kentucky, Louisiana, and New Jersey). This accounts for
approximately 27.8% of the US population.
NHL subtypes were classified using the WHO 2008 lymphoma classification scheme based on the
ICD-O-3 site codes. The ICD-O-3 system codes for tumor site, histology, and malignant behavior
(International Agency for Research of Cancer (IARC), 2018). The WHO 2008 scheme classifies by
morphology and grade of tumor (NCI, 2018). Subtypes and codes are listed in Table 1. Some rare
subtypes were excluded due to the low number of cases, which precluded analysis.
For this study, eligible patients were at least 20 years of age and diagnosed with NHL between
2000 and 2015. Individuals under the age of 20 were excluded because most NHL subtypes are rare in
younger populations (Georgakis et al., 2016). Age at diagnosis was coded as 20-29, 30-39, 40-49, 50-59,
60-69, ≥70. Race was limited to white, black, API, or AI/AK. Ethnicity was defined as
Spanish/Hispanic/Latino (Hispanic) or non-Spanish/Hispanic/Latino (non-Hispanic). The “unknown” race
group and age group were excluded. Only the first matching record for each person was used. This
resulted in 259,228 incident cases. Incidence per 100,000 was age-standardized to the 2000 U.S.
standard population using SEER*Stat software. We used the WHO classification scheme revised in 2008
for this study because it is recognized as the least controversial classification scheme (Campo et al.,
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2011). Subtypes, along with the WHO classification and corresponding ICD-O-3 codes, are shown in
Table 1.
Table 1. WHO Subtypes and Corresponding ICD-O-3 codes.
Subtype
WHO Subtype
Chronic lymphocytic
2(a)2.1.1. Chronic/Small lymphocytic leuk/lymph
leukemia/Small
lymphocytic
lymphoma (CLL/SLL)
Mantle-cell lymphoma 2(a)2.1.3. Mantle-cell lymphoma
(MCL)
Lymphoplasmacytic
2(a)2.2.1. Lymphoplasmacytic lymphoma
lymphomas (LPL)
2(a)2.2.2. Waldenstrom macroglobulinemia
Diffuse large B-cell
2(a)2.3.1. DLBCL, NOS
lymphoma (DLBCL)
2(a)2.3.2. Intravascular large B-cell lymphoma
2(a)2.3.3. Primary effusion lymphoma
2(a)2.3.4. Mediastinal large B-cell lymphoma
Burkitt lymphoma (BL) 2(a)2.4. Burkitt lymphoma /leukemia
Marginal-zone
2(a)2.5.1. Splenic MZL
lymphoma (MZL)
2(a)2.5.2. Extranodal MZL, MALT type
2(a)2.5.3. Nodal MZL
Follicular Lymphoma
2(a)2.6. Follicular Lymphoma
(FL)
Cutaneous T-cell
2(b)2.1.1. Mycosis fungoides
lymphomas (CTCL)
2(b)2.1.2 Sezary syndrome
Peripheral T-cell
2(b)2.2.1. Peripheral T-cell lymphoma, NOS
lymphoma (PTCL)
2(b)2.2.2. Angioimmunoblastic T-cell lymphoma
2(b)2.2.3. Subcutaneous panniculitis-like T-cell
lymphoma
2(b)2.2.4. Anaplastic large cell lymphoma, T- or Nullcell
2(b)2.2.5. Hepatosplenic T-cell lymphoma
2(b)2.2.6. Enteropathy-type T-cell lymphoma
2(b)2.2.7. Cutaneous T-cell lymphoma, NOS
2(b)2.2.8. Primary cutaneous anaplastic large cell
lymphoma

ICD-O-3 codes
9670, 9823

9673
9671, 9761
9680, 9688, 97379738, 9684, 9712,
9678-9679
9687, 9826
9689, 9699, 9760,
9764
9690-9691, 9695,
9698
9700, 9701
9702, 9675, 9705,
9708, 9714, 9716,
9717, 9718, 9709,
9726

Age-adjusted incidence rates were calculated using SEER*Stat 8.3.5 statistical software.
Incidence rates between groups are considered to be significantly different when 95% confidence
intervals (CI) between groups do not overlap. The relative risk or incidence rate ratio (RR) was calculated
to compare female incidence to male incidence; black, AI/AN, and API incidence to white incidence; and
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Hispanic incidence to non-Hispanic incidence. RRs are considered statistically significant when 95% CIs
do not include 1.
Joinpoint Regression Program 4.6.0.0 was used to visualize incidence trends and calculate
annual percentage change (APC). Joinpoint uses regression analysis and identifies significant changes in
annual incidence rates. Any point in time that represents a significant trend change is called a “joinpoint.”
Incidence trends from 2000 to 2015 were calculated using weighted least squares for non-constant
variance and log transformation of the dependent variable. APC was statistically different from zero
when p<0.05. When there were zero cases for a group, Joinpoint could not process the records to
calculate APC. Therefore, some groups did not have calculated APC.
Results
Age-Adjusted Incidence Rates and Time Trends for All Subtypes Combined
Between 2000 and 2015, there were a total of 259,288 incident cases of NHL. The age-adjusted
incidence rate of NHL (all subtypes combined) in 2000 and 2015 was 27.8 per 100,000 population (95%
CI: 27.35, 28.25) and 23.82 per 100,000 population (95% CI: 23.46, 24.19), respectively (Figure 1). The
Joinpoint analysis indicates that the age-adjusted rate actually increased from 2000 to 2004 (APC 0.76%,
p<.05) but then the decreased between 2004 and 2015 (2004-2008: APC -1.13%, p<0.05; 2008-2015 2.10%, p<0.05) (Table 2).
The age-adjusted incidence rate for males has been consistently higher than that of females
during the study period (Figure 2, Table 3). For instance, in 2015 the age-adjusted rate was 29.05 per
100,000 for males and 19.5 per 100,000 for females. For males, the age-adjusted incidence rate
increased from 2000 to 2005 and then decreased from 2005 to 2015 (APC -1.94%, p<0.05). For females,
there was an increase in the age-adjusted incidence rate from 2000 to 2004 (APC 1.51%, p<0.05) and a
decrease from 2004 to 2015 (APC -1.80%, p<0.05) (Figure 2, Table 2).
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Age-adjusted incidence rate has been consistently higher in older age groups compared to
younger age groups throughout the study period (Figure 3). In 2015, the age-adjusted incidence rate per
100,000 population was 85.29 for the 70+ group, 50.83 for the 60-69 group, 25.19 for the 50-59 group,
10.61 for the 40-49 group, 4.52 for the 30-39 group, and 2.27 for the 20-29 group. For the 70+ group,
age-adjusted incidence rate increased from 2000 to 2005 (APC 1.34%, p<0.05) and decreased from 2005
to 2015 (APC-2.21%, p<0.06). For the 60-69 group, an increase in the age-adjusted rate occurred from
2000 to 2003 and a decrease from 2003 to 2015 (APC-1.68%, p<0.05). For the 50-59 group, age-adjusted
rates have been decreasing from 2000 to 2015 (APC-1.18%, p<0.05). For the 40-49 group, rates
decreased from 2000 to 2008 and decreased more drastically from 2008 to 2015 (APC-2.29, p<0.05). For
the 30-39 group, a decrease occurred from 2000 to 2015 (APC -0.98%, p<0.05). For the 20-29 group, an
insignificant increase has been occurring since 2000 (APC 0.11%), though it should be noted that rates
were still lower than all other age groups throughout the study period (Table 2).
The overall age-adjusted incidence rate for whites has been consistently higher than all other
races during the study period. In 2015, age-adjusted incidence rate per 100,000 was 25.88 for whites,
17.40 blacks, 11.58 for AI/AN, and 15.41 for API (Figure 4). For whites, an increase occurred from 2000
to 2006 and a decrease occurred from 2006 to 2015 (APC-1.93%, p<0.05). For blacks, a decrease has
occurred throughout the study period (APC -0.94%, p<0.05). This is also true for AI/AN (APC -1.18%) and
API (APC -1.02%, p<0.05) (Table 2).
Overall age-adjusted rate for non-Hispanics has also been consistently higher than Hispanics
throughout the study period (Figure 5). In 2015, age-adjusted incidence rate was 24.6 per 100,000 for
non-Hispanics and 19.31 per 100,000 for Hispanics. From 2000 to 2003, rates increased in non-Hispanics.
Rates decreased from 2003 to 2008 and more drastically from 2008 to 2015 (APC -2.06%, p<0.05). For
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Hispanics, rates have been decreasing since 2000, but decrease was only significant from 2010 to 2015
(APC -2.9%, p<0.05) (Table 2).
Age-Adjusted Incident Rates by Subtype
For the period 2000-2015, the overall age-adjusted incidence rate for all subtypes combined was
26.9 per 100,000 population (Table 3). The incidence rate per 100,000 population was the highest for
diffuse large B-cell lymphoma (8.70) followed by chronic lymphocytic leukemia/small lymphocytic
lymphoma (7.24) and follicular lymphoma (4.45). Age-adjusted incidence rates increased as age
increased for all subtypes. As far as the sex difference, for all subtypes males had higher incidence rates
than females except for marginal-zone lymphoma, in which there was no statistical difference between
males and females (Table 3). Age-adjusted incidence rates were highest in whites for all subtypes except
cutaneous T-cell lymphoma and peripheral T-cell lymphoma, in which blacks had the highest incidence
rates (RR=1.65, p<0.05; RR=1.90, p<0.05) (Table 3). AI/AN had the lowest incidence rates for all subtypes
except chronic lymphocytic leukemia/small lymphocytic lymphoma and Mantle-cell lymphoma , in which
API and blacks had the lowest incidence rates, respectively. Finally, non-Hispanics had higher ageadjusted incidence rates than Hispanics for all subtypes except Diffuse Large B-Cell Lymphoma and
Burkitt lymphoma, in which Hispanics had significantly higher incidence (RR=1.05, p<0.05; RR=1.17,
p<0.05) (Table 3).
Time Trend in Age-Adjusted Incidence Rate for All Subtypes
Figures 6-14 show the Joinpoint analysis results for different subtypes. The age-adjusted
incidence rates have been decreasing since 2004 in chronic lymphocytic leukemia/small lymphocytic
lymphoma (APC -2.63%, p<0.05) (Figure 6). The Mantle-cell lymphoma incidence rate has been
increasing since 2000 (APC 0.77%, p<0.05) (Figure 7). Lymphoplasmacytic lymphomas incidence rate has
been decreasing since 2000 (APC -2.01%, p<0.05) (Figure 8). Incidence rate has been decreasing since
9

2003 in diffuse large B-cell lymphoma (APC -1.11%, p<0.05) (Figure 9), since 2009 in Burkitt lymphoma
(APC -7.06%, p<0.05) (Figure 10), since 2007 in marginal-zone lymphoma (APC -1.14%) (Figure 11), and
since 2006 in follicular lymphoma (APC -3.48%, p<0.05) (Figure 12). Incidence rate has been steady in
cutaneous T-cell lymphoma (mycosis fungoides and Sezary) syndrome (APC -0.03%) (Figure 13).
Incidence rate has been decreasing since 2000 in peripheral T-cell lymphoma (APC -2.08%, p<0.05)
(Figure 14).
Analysis of subtype time trends by demographic subgroups revealed more hidden trends. For
marginal-zone lymphoma, incidence time trends have been decreasing in the overall population (APC 1.14%) (Figure 11) and in males (APC -2.01%, p<0.05) but has been increasing in females (APC 0.47%)
(Table 2). For all subtypes, incidence rates increased as age increased. However, for some subtypes,
incidence trends measured by APC were different for different age groups (Table 2). For mantle-cell
lymphoma, the overall APC for all age groups was 0.77% (p<0.05) (Figure 7). However, the APC for the
30-39 age group 6.25% (p<0.05), more than 8 times the overall APC. For Burkitt lymphoma, overall
incidence increased from 2000-2009 (APC 1.73%) and has been decreasing since 2009 (APC -7.06%,
p<0.05). However, in the 20-29 age group, it has been increasing (APC 1.00%) since 2000 (Table 2). For
racial time trends, there were many differences. For marginal zone lymphoma, overall incidence has
been decreasing since 2007 (APC-1.14%, p<0.05) (Figure 11), but in blacks it has been increasing (APC
0.98%). For lymphoplasmacytic lymphomas, overall incidence has been decreasing since 2000 (APC2.01%, p<0.05). While this is consistent across most demographic groups, it is lower in the black
population (APC -0.19%) (Table 2). For trends in marginal-zone lymphoma, Hispanic population
incidence trends have been constant (APC-0.03%) while the overall population has been decreasing
since 2007 (APC-1.14%, p<0.05) (Table 2). For follicular lymphoma, overall trends have been decreasing
since 2006 (APC-3.48%, p<0.05) and this pattern is reflected in all groups except the Hispanic group, in
which has remained relatively constant (APC 0.08%) (Table 2).
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Discussion
We examined the incidence rate trends of NHL by subtype and demographic factors using SEER
18 program data 2000-2015. Findings from this study are mostly consistent with findings from studies
using earlier data – the increase in the age-adjusted incidence rates slowed down since the 1990s (Howe
et al., 2001). Chiu and Hou (2015) reported that this trend continued into the early 2000s and leveled off.
Time Trends by Subtype
The subtype with the most notable time trend was observed for Mantle-cell lymphoma. The
age-adjusted incidence rate increased between 2000 and 2015 for Mantle-cell lymphoma while the rate
decreased for many other subtypes during the same period. It is unlikely that the increase is due to
improved detection since increase in incidence was mostly limited to stage IV (Zhou et al., 2008). Clinical
symptoms do not manifest until late stages, making it difficult to detect and treat and giving Mantle-cell
lymphoma the poorest prognosis of all subtypes of NHL (Zhou et al., 2008). Early diagnosis of Mantle-cell
lymphoma continues to be a challenge as the incidence rate continues to increase.
Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) incidence has stabilized,
which is consistent with findings in other studies. A study of the 1973-2009 SEER registry found that APC
increased from 1973 to 1998 (APC 5.7%) and has been stable from 1998 to 2009 (APC 0.1%) (Korgavkar,
Xiong, & Weinstock, 2013). This study showed that trends have not changed since 2009. This
stabilization of incidence is thought to be due to improved detection in the 70’s (which would have
caused the increase) reaching a natural maximum presently as physicians can now detect all cases.
Though this would appear to be a stabilization of incidence, the reason for stabilization is largely
unknown (Korgavkar, Xiong, & Weinstock, 2013).
The decline in age-adjusted incidence rates of all other subtypes may be due to a number of
reasons. Hardell & Eriksson (2003) hypothesized that the decline was due to a decrease in chemical
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exposure to phenoxyacetic acids and chlorophenols. These chemicals were used as herbicides in the
1970s but they have since been prohibited, thus becoming less prominent in the environment. The
reduction in exposure eventually led to a reduction in the disease. Hardell & Eriksson (2003) along with
many others (Clarke & Glaser, 2002; Grulich et al., 2000), have also shown that the increase in the 70’s
and 80’s coincided with the Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency
Syndrome (AIDS) epidemic. Studies have shown that prolonged immune deficiency greatly increases risk
for NHL (Grulich et al., 2000). The slowing incidence, and now decrease, is thought to be due to the
introduction of successful antiviral therapy (Shiels et al., 2013). However, the increase in Mantle-cell
lymphoma incidence rates does not follow this.
Age-Adjusted Incidence Rates by Subtype
This study found that incidence rates differed by sex, race, and ethnicity in some subtypes. Most
notable was the higher incidence in blacks compared to whites in cutaneous T-cell lymphomas (mycosis
fungoides and Sezary syndrome) and peripheral T-cell lymphomas. This has been confirmed in many
studies using older data and the disparity continues, but the reason is not known (Imam et al., 2013;
Korgavkar, Xiong, & Weinstock, 2013). Imam et al (2013) recommended controlling for factors not in the
SEER database such as access to care, referral rate to dermatologists, and insurance coverage to
understand if the disparity is due socioeconomic factors or biological factors.
Marginal-zone lymphoma presented difference in age-adjusted incidence rates between men
and women compared to other subtypes. While all other subtypes showed higher male incidence rates,
marginal-zone lymphoma showed that male and female incidence rates were not statistically different
(RR=0.99, 95% CI: 0.96, 1.01). Female incidence rates were higher than male incidence rates in white,
AI/AN, and blacks, but was only significant in blacks (RR=1.1, p<0.05). Female incidence rates were also
higher in all age groups, except the 70+ age group. This may be explained by the association between
12

marginal-zone lymphoma and autoimmune diseases and Helicobacter pylori infection. Marginal-zone
lymphoma of mucosa-associated lymphoid tissue (MALT), the most common type of marginal-zone
lymphoma, is associated with autoimmune disease inflammation and gastritis due to H. pylori. Because
autoimmune diseases are more prevalent in women and H. pylori infection has similar prevalence in
men and women, this is thought to balance out the incidence rates between men and women (Morton
et al., 2006; Kiesewetter et al., 2016).
Although most subtypes of NHL are rare in children, Burkitt lymphoma is one of the most
common subtypes of NHL found in children and is rare in adults (Georgakis et al., 2016). When
comparing the age-adjusted incidence rates of Burkitt lymphoma in the 20-29 age group to the 70+ age
group, the difference is not as great compared to other subtypes (RR=3.42, p<0.05) (Table 3). Time
trends have also been increasing in the 20-29 age group (APC 1.00%) while they has been decreasing
since 2007 in all other subtypes (APC –7.06%, p<0.05). As far as we are aware, the higher incidence rates
in Hispanics compared to non-Hispanics (RR=1.16, P<0.05) in Burkitt lymphoma are not reported in any
other studies, although this is a more recent trend and may not have been adequately explored yet.
Endemic Burkitt lymphoma, a type found in Africa, is very well understood and is linked to Epstein - Barr
virus (EBV) and Plasmodium falciparum malaria infection. Sporadic Burkitt lymphoma, a type found in
the United States, is not strongly linked to EBV. Additionally, since malaria is not a prevalent issue in the
United States, sporadic Burkitt lymphoma’s epidemiology and etiology are not well-understood. As of
2005, it is known to be one of the most common childhood non-Hodgkin lymphomas and is more
common in males than females (Mbulaiteye et al., 2009).
Diffuse large B-cell lymphoma is another subtype in which Hispanic incidence rates are higher
than non-Hispanic incidence rates (RR=1.05, p<0.05). Li et al (2015) found this to be true only in females;
males still had higher non-Hispanic incidence rates compared to Hispanics. Further analysis by sex in this
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study found that Hispanic incidence rates were higher than non-Hispanic incidence rates for females
only, also. However, in males, the non-Hispanic and Hispanic incidence rates were identical - something
not reported in other studies.
Summary
Many of the findings in this study were corroborated by past studies in terms of age-adjusted
incidence rates by subtypes and subgroups. Similarly, many trends seemed to continue logically from
past studies with data before the year 2000. However, there were some new findings that have not
been reported in any published studies, to our best knowledge. Many of these were related to APC in
different age groups not following the same trends as the overall APC in subtypes. The APC in the 30-39
age group for Mantle-cell lymphoma (APC 6.25, p<0.05) was significantly higher than the overall APC
(0.77%, p<0.05). Marginal-zone lymphoma incidence has been increasing in the 20-29 age group (APC
1.47%), 30-39 age group (APC 2.97%, p<0.05) when the overall incidence has been decreasing (APC –
1.14%). Overall cutaneous T-cell lymphoma incidence has been stable but has been increasing in the 2029 (APC 2.39%) and 30-39 (APC 2.36%) age groups. Peripheral T-cell lymphoma incidence has but
decreasing (APC -2.08%, p<0.05), but is increasing in the 20-29 age group (APC 1.55%).Further analysis
comparing age groups between sexes or among races may reveal trends that are more meaningful.
These trends may also predict that incidence will rise or fall in certain age groups due to new risk factors
that are not yet apparent.
One of the limitations of this study is the existence of multiple classification systems and
constant changing of classification. Many subtypes have been re-coded many times, making it difficult to
correctly classify subtypes over a long period of time. The last WHO recode occurred in 2008, meaning
that some subtypes may have been coded differently previously. As classification schemes evolve, the
number of not otherwise specified (NOS) cases decrease. The incidence of some subtypes may appear to
14

increase after a subtype is no longer classified as NOS and given a new classification. Additionally, some
subtypes such as diffuse large B-cell lymphoma and peripheral T-cell lymphoma included many types
within themselves (Table 1). Some of these types may need to be classified as their own subtype
because their epidemiological or etiological differences may influence discrepancies in trends and rates.
Another limitation lies in the reporting of cases in the AI/AN population. Only cases that are within a
Contract Health Service Delivery Area (CHSDA) are included in SEER data (NIH, 2018). Therefore, data is
sporadic may not be representative of actual NHL incidence in the AI/AN population. Finally, the registry
only includes data for 27.8% of the US population until 2015, so it is not representative of the entire
current U.S. population. Strengths of this study include the sheer size of the sample (259,228 incident
cases) and the use of the most current and accurate WHO classification scheme and ICD-O-3 codes. The
SEER data was very diverse in terms of geographical area, age, race, and ethnicity.
Moving forward, differences in incidence rates and trends found in this study can be used as
hypotheses for future studies to better understand the epidemiology and determine etiology of these
cancers. Further sub-analysis can also be performed, such as comparing racial trends among different
age groups or between sexes, to reveal more hidden rates and trends that might help us understand
more about subtypes. Additionally, some subgroups that were not analyzed in this study such as
geographical location and stage of cancer may also provide more epidemiological information. The SEER
database is very useful for analyzing data, but it does not include some variables that may be crucial in
understanding differences in trends and rates such as access to care, patient compliance, education
level, or insurance coverage. If such data could be merged with the data available in SEER’s database, we
might be able to better explain variations in incidence among subtypes and subgroups.
NHL is a very complex and diverse group of cancers. The etiology of most subtypes remains
largely unknown. Continued data collection and analysis as well as further development classification
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schemes are needed to understand and interpret the differences in trends and rates in subtypes. This
understanding can help identify etiology and help reduce risks and prevent new cases. Despite certain
limitations, the findings of this study can be a stepping stone in predicting and preventing new NHL
cases.
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Tables and Figures

Figure 1. Age-adjusted NHL incidence rate 2000-2015: SEER 18 Program
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Figure 2. Comparing overall NHL incidence trends between males and females.
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Figure 3. Comparing overall NHL incidence trends among age groups.
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Figure 4. Comparing overall NHL incidence trends among races.
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Figure 5. Comparing overall NHL incidence trends between Hispanic/non-Hispanic groups.
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Age-Adjusted Incidence Rate of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, 2000-2015

Figure 6. Age-Adjusted Incidence Rate Time Trend for CLL/SLL
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Age-Adjusted Incidence Rate of Mantle-Cell Lymphoma, 2000-2015

Figure 7. Age-Adjusted Incidence Rate Time Trend for MCL
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Age-Adjusted Incidence Rate of Lymphoplasmacytic lymphomas, 2000-2015

Figure 8. Age-Adjusted Incidence Rate Time Trend for LPL
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Age-Adjusted Incidence Rate of Diffuse Large B-Cell Lymphoma, 2000-2015

Figure 9. Age-Adjusted Incidence Rate Time Trend for DLBCL
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Age-Adjusted Incidence Rate of Burkitt Lymphoma, 2000-2015

Figure 10. Age-Adjusted Incidence Rate Time Trend for BL

30

Age-Adjusted Incidence Rate of Marginal-Zone Lymphoma, 2000-2015

Figure 11. Age-Adjusted Incidence Rate Time Trend for MZL
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Age-Adjusted Incidence Rate of Follicular Lymphoma, 2000-2015

Figure 12. Age-Adjusted Incidence Rate Time Trend for FL
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Age-Adjusted Incidence Rate of Cutaneous T-Cell Lymphomas, 2000-2015

Figure 13. Age-Adjusted Incidence Rate Time Trend for CTCL
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Age-Adjusted Incidence Rate of Peripheral T-Cell Lymphoma, 2000-2015

Figure 14. Age-Adjusted Incidence Rate Time Trend for PTCL

34

Table 2. Annual Percentage Change (APC) by Age, Sex, Race, and Ethnicity for each Subtype, 2000-2015

APC for CLL/SLL

APC for Mantle
Cell Lymphoma

APC for Lymphoplasmacytic
Lymphomas

APC for DLBCL

APC for Burkitt
lymphoma

APC for Marginal
Zone Lymphoma

APC for Follicular
Lymphoma

APC for
Cutaneous T-Cell
Lymphoma

APC for
Peripheral T-Cell
Lymphoma

APC for Total NHL

Sex
Male

2000-2004: 0.24
2004-2010: -2.15*
2010-2015: -3.75*

2000-2015: 0.62*

2000-2015: -2.55*

2000-2015: -0.85*

2000-2009: 1.99*
2009-2015: -6.44*

2000-2005: 5.39*
2005-2015: -1.09*

2000-2005: 2.02
2005-2015: -3.14*

2000-2015: -0.44

2000-2015: -2.28*

2000-2005: 0.34
2005-2015: -1.94*

Female

2000-2004: 1.82
2004-2015: -2.59*

2000-2015: 0.78

2000-2015: -1.48*

2000-2003: 1.77
2003-2015: -1.29*

2000-2010: 0.65
2010-2015: -10.58

2000-2015: 0.47

2000-2007: 0.88
2008-2015: -4.05*

2000-2015: 0.08

2000-2002: -7.06
2002-2015: -1.66*

2000-2004: 1.51*
2004-2015: -1.80*

White

2000-2006: 0.39
2006-2015: -2.74*

2000-2015: 1.12*

2000-2015: -1.88*

2000-2004: 0.04
2004-2015: -1.07*

2000-2009: 1.92
2009-2015: -7.13*

2000-2007: 3.42*
2007-2015: -1.33*

2000-2006: 1.47
2006-2015: -3.31*

2000-2015: -0.20

2000-2015: -2.37*

2000-2006: 0.41
2006-2015: -1.93*

Black

2000-2015: -1.99*

2000-2015: -0.53

2000-2015: -0.19

2000-2015: -1.11*

2000-2015: -0.77

2000-2015: 0.98

2000-2008: 0.89
2008-2015: -5.51*

2000-2015: 0.78

2000-2015: -0.71

2000-2015: -0.94*

AI/AN

2000-2015: -1.5

UNKNOWN

UNKNOWN

2000-3015: -0.89

UNKNOWN

2000-2015: -0.15

2000-2015: -2.86

UNKNOWN

UNKNOWN

2000-2015: -1.18

API

2000-2015: -2.12*

2000-2015: -0.38

2000-2015: -2.90

2000-2015: -0.37

2000-2015: -2.62*

2000-2015: -1.19*

2000-2015: -1.39*

2000-2015: -1.21

2000-2015: -1.43*

2000-2015: -1.02*

NSHL

2000-2004: 1.45
2004-2015: -2.37*

2000-2015: 0.80*

2000-2015: -1.8*

2000-2003: 1.00
2003-2015: -1.12*

2000-2003: -4.5
2003-2009: 3.37
2009-2015: -7.81*

2000-2002: 9.1
2002-2008: 1.54
2008-2015: -1.28*

2000-2006: 1.21
2006-2015: -3.68*

2000-2015: 0.10

2000-2015: -2.01*

2000-2003: 1.29
2003-2008: -0.86
2008-2015: -2.06*

SHL

2000-2015: -3.02*

2000-2015: 1.79*

2000-2015: -3.38*

2000-2015: -0.97*

2000-2015: -1.42

2000-2015: -0.03

2000-2015: -0.08

2000-2015: -0.86

2000-2015: -1.94*

2000-2010: -0.29
2010-2015: -2.90*

20-29

2000-2015: -1.62

UNKNOWN

UNKNOWN

2000-2015: -0.25

2000-2015: 1.00

2000-2015: 1.47

2000-2015: -4.58*

2000-2015: 2.39

2000-2015: 1.55

2000-2015: 0.11

30-39

2000-2015: -0.74

2000-2015: 6.25*

UNKNOWN

2000-2015: -1.49*

2000-2009: 5.4*
2009-2015: -9.91*

2000-2015: 2.97*

2000-2015: -2.44*

2000-2015: 2.36

2000-2015: -1.19

2000-2015: -0.98*

40-49

2000-2015: -1.42*

2000-2015: -0.03

2000-2015: -2.39

2000-2015: -1.32*

2000-2009: 3.41
2009-2015: -9.82*

2000-2015: -0.22

2000-2007: 0.82
2007-2015: -3.30*

2000-2015: 0.02

2000-2015: -1.41*

2000-2005: -0.35
2005-2015: -2.29*

50-59

2000-2015: -1.41*

2000-2015: 0.08

2000-2015: -3.7*

2000-2015: -0.61*

2000-2015: -0.95

2000-2002: 14.73
2002-2015: -0.46

2000-2004: 1.81
2004-2015: -2.80*

2000-2015: -1.02*

2000-2015: -2.36*

2000-2015: -1.18*

60-69

2000-2002: 5.13
2002-2015: -2.45

2000-2015: 0.48

2000-2015: -0.97*

2000-2015: -0.87*

2000-2015: -2.72

2000-2015: 0.5

2000-2004: 3.02
2004-2015: -3.01*

2000-2015: -0.16

2000-2015: -2.19*

2000-2005: 1.92
2005-2015: -1.68*

70+

2000-2005: 1.33
2005-2015: -3.25*

2000-2015: 1.25*

2000-2015: -1.91*

2000-2004: 1.26
2004-2015: -1.29*

2000-2013: -2.14*
2013:2015: -19.27*

2000-2008: 3.08*
2008-2015: -2.43*

2000-2005: 3.67
2005-2015: -3.54*

2000-2015: -0.88

2000-2015: -2.69*

2000-2005: 1.34*
2005-2015: -2.21*

2000-2004: 1.29
2004-2015: -2.63*

2000-2015: 0.77*

2000-2015: -2.01*

2000-2003: 0.94
2003-2015: -1.11*

2000-2009: 1.73
2009-2015: -7.06*

2000-2007: 2.70*
2007-2015: -1.14

2000-2006: 1.25
2006-2015: -3.48*

2000-2015: -0.03

2000-2015: -2.08*

2000-2004: 0.76
2004-2008: -1.13
2008-2015: -2.10*

Race

Ethnicity

Age Group

Total

*APC is significantly different from 0
UNKNOWN means Joinpoint was unable to calculate APC due to incidence rate being 0 for at least one year
Green represents significant increases, red represents significant decreases
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Table 3. Age-Adjusted Incidence Rates by Age, Sex, Race, and Ethnicity for each Subtype, 2000-2015
Incidence Rate for
NHL total

Incidence Rate for
CLL/SLL

Incidence Rate for
Mantle Cell
Lymphoma

Incidence Rate
for Lymphoplasmacytic
Lymphomas

Incidence Rate
for DLBCL

Incidence Rate
for Burkitt
lymphoma

Incidence Rate
for Marginal
Zone
Lymphoma

Incidence Rate
for Follicular
Lymphoma

Incidence Rate
for Cutaneous
T-Cell
Lymphoma

Incidence Rate
for Peripheral
T-Cell
Lymphoma

26.9

7.24

0.94

0.8

8.7

0.41

2.33

4.45

0.59

1.44

20-29

2.35

0.04

0

0.01

1.26

0.23

0.15

0.19

0.14

0.33

30-39

5.34, RR=2.27*

0.31, RR=8.50*

0.05, RR=14.47*

0.03, RR=3.55*

2.41, RR=1.91*

0.33, RR=1.41*

0.40, RR=2.33*

0.96, RR=5.03*

0.29, RR=2.12*

0.55, RR=1.70*

40-49

12.28, RR=5.23*

1.84, RR=50.00*

0.29, RR=79.18*

0.17, RR=19.52*

4.38, RR=3.47*

0.43, RR=1.83*

1.04, RR=6.86*

2.77, RR=14.41*

0.46, RR=3.40*

0.90, RR=2.77*

50-59

28.75, RR=12.24*

6.91, RR=188.32*

1.06, RR=288.42*

0.69, RR=77.65*

8.49, RR=6.74*

0.44, RR=1.90*

2.62, RR=17.30*

6.12, RR=31.87*

0.79, RR=5.82*

1.62, RR=4.98*

60-69

62.27, RR=26.51*

18.21, RR=495.91*

2.63, RR=716.44*

1.91, RR=214.09*

17.80, RR=14.12*

0.54, RR=2.32*

5.69, RR=37.53*

11.13, RR=58.02*

1.31, RR=9.64*

3.05, RR=9.36*

70+

114.78, RR=48.88*

36.15, RR=984.84*

4.44, RR=1,208.82*

4.29, RR=481.43*

37.08, RR=29.42*

0.80, RR=3.42*

9.99, RR=65.91*

15.32, RR=79.81*

1.62, RR=11.89*

5.09, RR=15.65*

Male

32.96

9.7

1.48

1.07

10.45

0.6

2.36

4.77

0.73

1.8

Female

22.05, RR=0.67*

5.32, RR=0.55*

0.51, RR=0.35*

0.60, RR=0.56*

7.25, RR=0.69*

0.22, RR=0.37*

2.33, RR=0.99

4.19, RR=0.88*

0.48, RR=0.66*

1.14, RR=0.63*

White

28.96

8.02

1.06

0.88

9.11

0.43

2.44

5.03

0.57

1.42

Total

Age

Sex

Race

Black

19.70, RR=0.68*

5.77, RR=0.72*

0.41, RR=0.39*

0.43, RR=0.49*

6.11, RR=0.67*

0.36, RR=0.84*

1.81, RR=0.74*

2.04, RR=0.40*

0.88, RR=1.54*

1.90, RR=1.34*

AI/AN

12.01, RR=0.41*

2.20, RR=0.25*

0.50, RR=0.47*

0.26, RR=0.30*

4.80, RR=0.53*

0.19, RR=0.44*

1.21, RR=0.50*

1.89, RR=0.37*

0.27, RR=0.47*

0.70, RR=0.49*

API

16.48, RR=0.57*

1.87, RR=0.23*

0.43, RR=0.40*

0.46, RR=0.52*

7.71, RR=0.85*

0.33, RR=0.78*

1.90, R=0.78*

2.21, RR=0.44*

0.43, RR=0.75*

1.14, RR=0.80*

NSHL

27.64

7.71

0.96

0.84

8.68

0.4

2.36

4.57

0.63

1.48

SHL

21.65, RR=0.78*

3.41, RR=0.44*

0.81, RR=0.88*

0.43, RR=0.51*

9.10, RR=1.05*

0.47, RR=1.17*

2.09, RR=0.89*

3.70, RR=0.81*

0.39, RR=0.63*

1.24, RR=0.84*

Ethnicity

*RR is significantly different from reference group for age, sex, race, and ethnicity
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